Validation of the CAMCOG-DS-II, a neuropsychological test battery for Alzheimer's disease in people with Down syndrome: A Horizon 21 European Down syndrome Consortium study.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ivain Phoebe, Baksh Asaad, Saini Fedal, Idris Mina, Tamayo-Elizalde Miren, Wells Jasmine, Benejam Bessy, Loosli Sandra Virginia, Sandkühler Katja, Wlasich Elisabeth, Wagemann Olivia, Levin Johannes, Martet Diane, Sacco Silvia, Falquero Ségolène, Clert Manon, Rebillat Anne-Sophie, Khoo Wan Ming, Smith Madelaine Amelia, Beresford-Webb Jessica, Zaman Shahid, Carmona-Iragui María, Videla Laura, Fortea Juan, Langballe Ellen Melbye, Medbøen Ingrid Tøndel, Larsen Frode Kibsgaard, Baldimtsi Eleni, Paradisi Raphaella, Ntailakis Panagiotis, Tsolaki Magdalini, Papantoniou Georgia, McGlinchey Eimear, McCarron Mary, Kennelly Seán, Strydom André
Аннотация
METHODS: In this multi-language, multi-site study, the psychometric properties of the CAMCOG-DS-II were evaluated against previously validated measures in 223 participants (mean age: 40.18 years) with DS across seven countries.
RESULTS: The CAMCOG-DS-II had a high completion rate, minimal floor/ceiling effects (compared to the modified Cued Recall Test, the CANTAB Paired Associates Learning, and the Purdue Pegboard), strong validity and reliability, and performance was unaffected by language across sites. It differentiated between those with/without AD and distinguished clinically rated cognitively stable and prodromal individuals.
CONCLUSION: The CAMCOG-DS-II is a sensitive measure of cognitive performance in people with DS at risk of AD. Its cross-language and site reliability support its potential use in AD-DS clinical trials.
HIGHLIGHTS: Developed and validated the Cambridge Cognitive Examination modified for use in people with Down syndrome (CAMCOG-DS-II) for Alzheimer's disease in Down syndrome. CAMCOG-DS-II shows increased sensitivity to Alzheimer's disease-related decline in Down syndrome. Improved applicability across an international and culturally diverse population. Differentiates Alzheimer's disease status: cognitively stable, prodromal, and clinical.